SCM
TNYA icon

Soleus Capital Management’s Tenaya Therapeutics TNYA Stock Holding History

Soleus Capital Management’s Portfolio TNYA Stock Details TNYA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-122,222
Closed -$639K – 110
2024
Q1 		$639K Buy
+122,222
New +$585K 0.05% 87

Other funds holding TNYA

CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Soleus Capital Management's TNYA Position: Q2 2024 in Review

Soleus Capital Management sold out of Tenaya Therapeutics (TNYA) in Q2 2024, closing a stake of 122,222 shares — an estimated $639K sold.

Soleus Capital Management first reported a position in TNYA in Q1 2024 and held it in 1 quarter. The position peaked at $639K in Q1 2024. 96 funds tracked by Wall St. Rank hold TNYA as of Q2 2024.

  • Soleus Capital Management reported no remaining Tenaya Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Soleus Capital Management sold 122,222 Tenaya Therapeutics shares in Q2 2024, an estimated $639K.
  • Soleus Capital Management first reported a position in Tenaya Therapeutics in Q1 2024 and held it in 1 quarter.
  • Soleus Capital Management's Tenaya Therapeutics position peaked at $639K in Q1 2024.
  • 96 funds tracked by Wall St. Rank held Tenaya Therapeutics as of Q2 2024.

Based on Soleus Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.